Torque Teno Virus load in lung cancer patients correlates with age but not with tumor stage

Dirk Stefani1, Balazs Hegedues1, Stephane Collaud1, Mohamed Zaatar1, Till Ploenes1, Daniel Valdivia1, Carina Elsner2, Barbara Bleekmann2, Marek Widera2,3, Ulf Dittmer2, Clemens Aigner1*

1 Department of Thoracic Surgery, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, 2 Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, 3 Institute of Medical Virology, University Hospital Frankfurt am Main, Goethe University, Frankfurt am Main, Germany

* clemens.aigner@rlk.uk-essen.de

Abstract

Background
Torque teno virus (TTV) is a ubiquitous non-pathogenic virus, which is suppressed in immunological healthy individuals but replicates in immune compromised patients. Thus, TTV load is a suitable biomarker for monitoring the immunosuppression also in lung transplant recipients. Since little is known about the changes of TTV load in lung cancer patients, we analyzed TTV plasma DNA levels in lung cancer patients and its perioperative changes after lung cancer surgery.

Material and methods
Patients with lung cancer and non-malignant nodules as control group were included prospectively. TTV DNA levels were measured by quantitative PCR using DNA isolated from patients plasma and correlated with routine circulating biomarkers and clinicopathological variables.

Results
47 patients (early stage lung cancer n = 30, stage IV lung cancer n = 10, non-malignant nodules n = 7) were included. TTV DNA levels were not detected in seven patients (15%). There was no significant difference between the stage IV cases and the preoperative TTV plasma DNA levels in patients with early stage lung cancer or non-malignant nodules (p = 0.627). While gender, tumor stage and tumor histology showed no correlation with TTV load patients below 65 years of age had a significantly lower TTV load than older patients (p = 0.022). Regarding routine blood based biomarkers, LDH activity was significantly higher in patients with stage IV lung cancer (p = 0.043), however, TTV load showed no correlation with LDH activity, albumin, hemoglobin, CRP or WBC. Comparing the preoperative, postoperative and discharge day TTV load, no unequivocal pattern in the kinetics were.
Conclusion
Our study suggest that lung cancer has no stage dependent impact on TTV plasma DNA levels and confirms that elderly patients have a significantly higher TTV load. Furthermore, we found no uniform perioperative changes during early stage lung cancer resection on plasma TTV DNA levels.

Introduction
The ubiquitous Torque teno virus (TTV) has a high prevalence of about 90% in the population worldwide [1–3]. It was initially detected in 1997 in a patient with post transfusion hepatitis in Japan [4]. TTV is a single stranded circular Anellovirus from the Circoviridae family of about 3.8 kilobases [5]. It leads to a low viremia in immune competent hosts [6]. TTV viral load increases during the first months of healthy infants development [7].

While TTV infection had been suggested to be associated epidemiologically with many diseases like respiratory [8], hepatic [9] or hematological disorders [10] and cancer [11], a direct causal link between TTV infection and specific diseases is lacking. Therefore, the overall consensus now is that TTV is nonpathogenic [6]. However, TTV DNA load was demonstrated as a suitable surrogate marker for immune competence [12–17]. TTV DNA plasma loads were found to be elevated in patients under immunosuppression after lung transplantation and other solid organ transplantations [16, 18]. The extent of TTV viremia correlates with the state of immunosuppression of the transplant recipient [19] and works as a predictor for the development of rejection and infection in lung transplantation [15]. TTV plasma DNA levels can therefore be used as a marker for monitoring the extent of immunosuppression in lung [20], kidney [21] and liver transplant recipients [22].

The association of TTV DNA levels with carcinogenesis and clinical course of lung cancer is poorly understood. TTV DNA has been found in a variety of neoplastic tissues including lung cancer [11]. Furthermore, TTV load was significantly higher in the peripheral blood mononuclear cells from cancer patients with various malignancies than in the PBMC from healthy blood donors [23]. Previously it has been demonstrated that patients suffering from both idiopathic pulmonary fibrosis (IPF) and lung cancer have higher TTV DNA levels than lung cancer only or IPF only patients. Of note, TTV loads did not match with tumor stages among these patients with lung cancer complicated with IPF [8]. Among platinum based chemotherapy treated advanced stage lung cancer patients the TTV DNA levels decreased after therapy in the partial response/stable disease subgroup and increased in the progressive disease subcohort which led to the hypothesis that high TTV loads may correlate with higher tumor load and thus with tumor stage [24].

In chronically infected individuals, TTV viremia fluctuates very little over periods of weeks or months indicative of the existence of a quasi-steady-state virus-host equilibrium resulting from balanced virus production and elimination. However, the dynamic nature of TTV viremia is highlighted by the observation that over 90% of the TTV virions found in the plasma of chronically infected subjects turns over daily [25]. Furthermore, significant changes of TTV load can be detected as early as three days after alpha-interferon treatment in Hepatitis C patients [25].

Accordingly, we analyzed the TTV plasma DNA load in early and advanced stage lung cancer patients as well as monitored its perioperative changes after curative intent resection.
Materials and methods

Patients

47 patients were included prospectively in the study from January 2019 to January 2020. Current immunosuppressive medication and chemotherapy within the previous 12 months were exclusion criteria. 30 patients with early stage lung cancer underwent curative intent surgery (23 (bi-) lobectomy, 4 sleeve-lobectomy, 3 segmentectomy). Resected lung tumors were pathologically staged (pT and pN) by using the UICC 8th edition of lung cancer TNM staging. 10 patients had stage IV lung cancer and tumor size (cT) and lymph node involvement (cN) was assessed by radiological staging. In the non-malignant group diagnoses included hamartochondroma (n = 2), organizing pneumonia (n = 3) and necrotizing granulomatosis (n = 2). Pathological tumor stage, histology, procedure, operation time, blood loss, major and relevant pre-existing conditions or events and postoperative complication of the patients under investigation were registered. Routine blood parameters including amounts of white blood cell counts (WBC), concentrations of albumin, hemoglobin, lactate dehydrogenase (LDH) and C-reactive protein (CRP) were also measured preoperatively. Plasma was collected prior to the operation, one day after surgery and at discharge (4 to 9 days). Plasma samples were collected from stage IV patients once during their hospital stay for staging purposes but prior to any procedure. All plasma samples were collected in collaboration with the Westgerman Biobank Essen (WBE). Every patient provided written informed consent. The study was approved by the Ethics Committee of the University Duisburg-Essen (#18–8539) and was conducted in compliance with the Declaration of Helsinki.

Quantification of TTV DNA

TTV DNA was isolated from 200 µl of patient plasma using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany; #51106) following the manufacturer’s instruction. DNA was subjected to real-time PCR analysis as described [16, 17, 26] using the Rotor-Gene Probe PCR Kit (Qiagen, #204374). TTV specific primers and a 5’FAM / 3’TAMRA labeled probe [26] were purchased from metabion GmbH (Planegg/Steinkirchen, Germany). As a positive control for DNA quality we used human GAPDH specific primers and a 5’YAK/3’BQQ labeled probe purchased from TIB MOLBIOL (Berlin, Germany). The primer sequences were as follows according to PrimerBank ID 378404907c1: forward 5’ GGCTGTTGTCATACCTCTCATGG, reverse 5’ GGCTGTTGTCATACCTCTCATGG. The probe has the following sequence: 5’ YAK-AGTG GGGCGATGCTGGCGCTGAG-BQQ. For absolute quantification we used GAPDH cDNA kindly provided by Dr. Kathrin Sutter (University Hospital Essen, Essen, Germany) to generate a standard curve. The cycling conditions on a Rotor–Gene-Q-Instrument (Qiagen) were as follows: initial denaturation was 10 min at 95˚C followed by 45 cycles of denaturation for 15 seconds and extension for 60 seconds at 58˚C. As described previously, TTV genotype 1a DNA (AB017610.1) cloned into a pCR2.1 vector was used to generate a DNA standard curve [16, 17, 26]. The limit of quantification (LOQ) was 50 copies per ml. Samples with copy numbers below the quantification limit were included in calculations with a value of LOQ/2 (i.e. 25 copies per ml) [27].

Statistical analysis

For continuous variables the normality of distribution was tested by Shapiro-Wilk test. For comparing two groups Mann-Whitney test was used. One-way analysis of variance (ANOVA) was performed for normally distributed parameters (age, albumin, hemoglobin) and Kruskal-Wallis test (TTV DNA levels, LDH) with Dunn’s multiple comparison test were used as non-
Correlation of TTV DNA levels with amounts of WBC, albumin, hemoglobin and LDH was analyzed by Spearman test. Contingency analysis of the three patient subcohort for categorical variables (gender, tumor stage, CRP) was compared with chi-square test. P-values of p < 0.05 were considered as significant. Statistical analysis was conducted using GraphPad Prism 5.0 software.

**Results**

The major clinicopathological characteristics and biomarker values for the early stage metastatic lung cancer patients as well as for the non malignant lung nodule patients are presented in Table 1.

The early stage subgroup (stage I-III) was representative for a curative intent resection cohort in terms of histology, access and stage distribution. There was no statistically significant difference between the three subgroups regarding gender (p = 0.146) and age (p = 0.134) or

| Table 1. Clinicopathological characteristics of the patient subgroups. |
|---------------------------------------------------------------|
| **Early stage lung cancer (n = 30)** | **Stage IV lung cancer (n = 10)** | **Non-malignant (n = 7)** |
| **Gender** | Male | 20 | 7 | 2 |
| | Female | 10 | 3 | 5 |
| **Age** | Mean±SD | 67.4±8.3 | 61.7±8.1 | 69.3±10.3 |
| **Operation** | VATS | 15 | n.a. | 6 |
| | Thoracotomy | 15 | n.a. | 0 |
| **Histology** | Adenocarcinoma | 12 | 8 | n.a. |
| | Squamous cell | 13 | 2 | |
| | Adenosquamous | 3 | | |
| | Neuroendocrine | 2 | | |
| **Stage (UICC 8th Edition)** | IA | 15 | n.a. | |
| | IB | 3 | | |
| | IIA | 4 | | |
| | IIB | 4 | | |
| | IIIA | 4 | | |
| | IVA | 5 | | |
| | IVB | 5 | | |
| **pT descriptor** | 1 | 16 | 0 | n.a. |
| | 2 | 9 | 3 | |
| | 3 | 2 | 2 | |
| | 4 | 3 | 5 | |
| **pN descriptor** | 0 | 26 | 1 | n.a. |
| | 1 | 4 | 0 | |
| | 2 | 0 | 7 | |
| | 3 | 0 | 2 | |
| **CRP** | <1 mg/dl | 19 | 4 | 6 |
| | >1 mg/dl | 11 | 6 | 1 |
| **albumin** | Mean±SD [g/dL] | 4.4±0.3 | 4.15±0.5 | 4.5±0.2 |
| **hemoglobin** | Mean±SD [g/dL] | 14.1±1.6 | 12.5±1.6 | 13.3±1.5 |
| **WBC** | Mean±SD [10^9/L] | 8.3±2.4 | 8.6±3 | 8.1±3.2 |
| **LDH** | Mean±SD [U/L] | 222±49 | 286±77 | 231±72 |

*one patient had no operation

VATS–Video Assisted Thoracic Surgery; CRP–C-reactive protein; WBC–white blood cells; LDH–lactate dehydrogenase; SD–standard deviation; n.a.–not applicable

https://doi.org/10.1371/journal.pone.0252304.t001
white blood cell counts ($p = 0.92$). High CRP values ($>1 \text{ mg/dl}$) tended to be more frequent in stage IV lung cancer patients ($p = 0.066$). LDH was significantly increased in stage IV lung cancer cases ($p = 0.043$, Table 1).

TTV DNA was not detectable in the blood of 7 patients (15%) including 4 early stage, 1 stage IV and 2 non-malignant cases. In all samples tested, GAPDH was amplified as a control and the GAPDH levels were comparable throughout the samples. TTV viral load did not show significant differences between early stage and advanced stage cases or in patients without malignancy ($p = 0.63$, Fig 1A). There was no significant difference in the TTV viral load between male and female patients ($p = 0.634$). In contrast patients younger than 65 years of age had significantly lower TTV viral loads than older patients ($p = 0.022$, Fig 1B).

TTV DNA viral load was also independent of histology (adenocarcinoma versus squamous cell carcinoma, $p = 0.433$). The pathological TNM tumor stage was defined by the UICC 8th edition. The TTV viral load showed no significant differences in the four TNM stage group (Fig 2, $p = 0.436$).

Furthermore, TTV load showed no correlation with albumin, hemoglobin, LDH and WBC values ($p = 0.781$, $p = 0.295$, $p = 0.127$ and $p = 0.608$, respectively). There was no significant difference in TTV copy numbers between CRP high ($\geq 1$) and low ($< 1$) ($p = 0.547$) or LDH high ($> 220$) and low ($< 220$) patients ($p = 0.155$, Fig 3).

Next, we analyzed whether the resection has an impact on TTV DNA levels. Absolute and relative TTV loads in early lung cancer patients and its perioperative changes after lung cancer surgery are shown in Fig 4. Preoperative TTV plasma DNA load showed a very wide range in lung cancer patients. Postoperative changes of TTV plasma DNA levels remained well below an order of magnitude (Fig 4A). 4 patients had a more than 50% increase and 7 patients a slightly more than 50% decrease in relative TTV plasma DNA load at postoperative day 1 (Fig 4B).

At discharge 4 and 6 patients demonstrated 50% increase or decrease in relative TTV plasma DNA levels, respectively.

Fig 1. Baseline TTV DNA levels. (A) There was no significant difference in the TTV copy numbers in the blood of early stage and stage IV lung cancer patients and patients without malignant lung tumors. (B) Patients older than 65 years of age had significantly lower TTV DNA levels in the blood ($p = 0.022$).

https://doi.org/10.1371/journal.pone.0252304.g001
Discussion

In the current study we measured the TTV plasma DNA levels in a lung cancer patient cohort and in a group of patients with non malignant lung nodules or other non malignant indication for lung operation. 15% of all patients had no detectable levels of TTV DNA in the DNA isolated from the patient’s plasma comparable to previous prevalence studies using blood donor collectives [3, 28].

In our patient population, older individuals had significantly higher TTV DNA levels. This finding is in line with previous investigations on smaller cohorts and with a large survey for markers of aging (MARK-AGE) [29–31]. Indeed, in the MARK-AGE study only age and

![Figure 2](https://doi.org/10.1371/journal.pone.0252304.g002)

**Fig 2.** TTV DNA levels in the lung cancer patients grouped by TNM stage (UICC 8th edition). There was no significant difference in the 4 stage groups (p = 0.436).

![Figure 3](https://doi.org/10.1371/journal.pone.0252304.g003)

**Fig 3.** Baseline TTV DNA levels in patients with normal and increased CRP or LDH. (A, B) There was no significant difference between the two groups, (p = 0.547 and p = 0.155).
gender showed a significant association with TTV loads but no blood based routine laboratory parameter did. We found no correlation between TTV load and gender, however, only 17 female patients (36%) participated in our study. Haloschan et al found lower TTV levels for women under the age of 30 when compared to men [31] but our patient cohort includes only patients older than 30 years of age. Confirming the findings of the MARK-AGE study [29], TTV DNA levels showed no significant association with the amount of hemoglobin, albumin, CRP or WBC in our cohort.

De Villiers et al found varying TTV positivity in tumor tissue samples from different types of cancer, however, the study did not compare different histologies within lung cancer [11]. Nevertheless, there is currently no data available whether lung cancer histology shows an association with TTV viral load in the patients plasma. Our case series consisted primarily from adenocarcinoma and squamous cell carcinoma, however, the lack of significant difference between the histologies should be carefully interpreted due to the relatively low case number.

Since TTV DNA load is a surrogate marker for immune competence in transplant patients [13, 15, 17, 18], we hypothesized that potential differences in immunocompetence based on the presence or disease stage of lung cancer might impact TTV DNA load in the patient's blood. However, we found no difference between the subcohorts with or without lung cancer. In line with our findings, Bando et al reported no differences between lung cancer patients and idiopathic pulmonary fibrosis (IPF) patients [8]. Interestingly, the aforementioned report found significantly higher TTV DNA titers in lung cancer patients with IPF. In our study disease stage showed no association with circulating TTV load confirming the previous report [8]. In this earlier study the majority of patients were in stage IV, in contrast to our study where the majority was early stage lung cancer. Nevertheless, both study supports the notion that circulating TTV DNA levels seem to be disease stage independent in lung cancer.

Regarding the association of TTV loads with the outcome of lung cancer therapy Sawata et al reported that TTV DNA levels decreased after platinum based chemotherapy treatment of...
advanced stage patients with partial response or stable disease. In contrast, TTV loads increased after chemotherapy in patients with progressive disease [24]. Due to the short follow-up time in our series, we can not investigate whether TTV DNA baseline values or its changes after surgery might correlate with outcome after curative intent lung resection. Advanced stage patients are the younger patients than patients in the early stage and non-malignant subgroup in our study. Therefore the TTV levels are in general lower because of the lower age, which could counteract and disguise a possible high TTV load in these patients.

The kinetics of TTV DNA during tumor progression is yet to be studied. Regarding the dynamics of TTV load, Maggi et al. calculated a more than 90 percent daily turnover for circulating TTV DNA and found significant decrease of plasma TTV levels already after three days of interferon treatment in Hepatitis C patients [25]. There are a couple of publications investigating changes in TTV loads after lung transplantation [15, 18]. In the majority of lung transplant recipients within two weeks after transplantation a marked increase can be observed due to immunosuppression. In cancer and specifically in lung cancer, the comparison of TTV DNA copy numbers before and after chemotherapy in a small advanced stage cohort demonstrated that depending on response to therapy the extent of TTV viremia can change in either direction [24]. In our early stage lung cancer patients there was no clear tendency for a decrease or increase of plasma TTV DNA levels on postoperative day 1 or at discharge (4 to 9 postoperative days). A previous study indicated that TTV DNA load in the peripheral blood mononuclear cells of cancer patients (not specifically lung cancer patients) is significantly higher when compared to PBMC from healthy donors [23]. Altogether, it remains an open question whether the tumor itself is a major site of viral replication. Long-term follow-up studies are warranted in order to investigate whether tumor resection or potentially tumor recurrence or progression has an impact on TTV loads.

Conclusion

Torque teno virus load in lung cancer patients does not associate with tumor stage in this study but is increased in elderly patients. Moreover, we found no correlation of TTV DNA levels with routine laboratory parameters. Finally, we identified perioperative changes in TTV viral load in patients undergoing curative intent lung cancer resection, however, the perioperative kinetics showed no unequivocal pattern.

Supporting information

S1 File.
(XLSX)

Acknowledgments

We thank Mrs. Eva Gottstein for her technical support in DNA isolation. We are indebted to the Westgerman Biobank Essen (WBE) for providing the blood samples.

Author Contributions

Conceptualization: Dirk Stefani, Clemens Aigner.

Data curation: Dirk Stefani, Balazs Hegedues, Stephane Collaud, Mohamed Zaatar, Till Ploenes, Daniel Valdivia, Carina Elsner, Barbara Bleekmann, Marek Widera, Ulf Dittmer.

Formal analysis: Dirk Stefani, Balazs Hegedues, Ulf Dittmer.

Investigation: Carina Elsner, Barbara Bleekmann, Clemens Aigner.
Supervision: Ulf Dittmer, Clemens Aigner.

Validation: Balazs Hegedues, Ulf Dittmer.

Writing – original draft: Dirk Stefani, Balazs Hegedues, Carina Elsner.

Writing – review & editing: Dirk Stefani, Balazs Hegedues, Stephane Collaud, Mohamed Zaatar, Till Ploenes, Daniel Valdivia, Carina Elsner, Barbara Bleekmann, Marek Widera, Ulf Dittmer, Clemens Aigner.

References

1. Huang L-Y, Jonassen TØ, Hungnes O, Grinde B. High prevalence of TT virus-related DNA (90%) and diverse viral genotypes in norwegian blood donors. Journal of Medical Virology. 2001; 64(3):381–6. https://doi.org/10.1002/jmv.1062 PMID: 11424130

2. Zhong S, Yeo W, Lin CK, Lin XR, Tang MW, Johnson PJ. Quantitative and genotypic analysis of TT virus infection in Chinese blood donors. Transfusion. 2001; 41(8):1001–7. https://doi.org/10.1046/j.1537-2995.2000.41005090.x PMID: 10827265

3. Biagini P, Galliani P, Touni SS, Cantaloube JF, Zapitelli JP, de Lamballerie X, et al. High prevalence of TT virus infection in French blood donors revealed by the use of three PCR systems. Transfusion. 2000; 40(5):590–5. https://doi.org/10.1046/j.1537-2995.2000.40050590.x PMID: 10827265

4. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochemical and biophysical research communications. 1997; 241(1):92–7. https://doi.org/10.1006/bbrc.1997.7765 PMID: 9405239

5. Okamoto H, Ukitaka M, Nishizawa T, Kishimoto J, Hoshi Y, Mizuo H, et al. Circular double-stranded forms of TT virus DNA in the liver. J Virol. 2000; 74(11):5161–7. https://doi.org/10.1128/jvi.74.11.5161-5167.2000 PMID: 10799591

6. Spandole S, Gimponeri D, Berca LM, Mihaescu G. Human anelloviruses: an update of molecular, epidemiological and clinical aspects. Arch Virol. 2015; 160(4):893–908. https://doi.org/10.1007/s00705-015-2363-9 PMID: 25680568

7. Tyschik EA, Rasskazov A S, Degtyareva AV, Rebrikov DV, Sukhikh GT. Torque teno virus dynamics during the first year of life. Virol J. 2018; 15(1):96. https://doi.org/10.1186/s12985-018-1007-6 PMID: 29843750

8. Bando M, Takahashi M, Ohno S, Hosono T, Hironaka M, Okamoto H, et al. Torque teno virus DNA titre elevated in idiopathic pulmonary fibrosis with primary lung cancer. Respiriology. 2008; 13(2):263–9. https://doi.org/10.1111/j.1440-1843.2007.01217.x PMID: 18339026

9. Tokita H, Murai S, Kamitsukasa H, Yahara M, Harada H, Takahashi M, et al. High TT virus load as an independent factor associated with the occurrence of hepatocellular carcinoma among patients with hepatitis C virus-related chronic liver disease. J Med Virol. 2002; 67(4):501–9. https://doi.org/10.1002/jmv.10129 PMID: 12115995

10. Garbuglia AR, Iezzi T, Capobianchi MR, Pignoloni P, Pulsoni A, Sourdis J, et al. Detection of TT virus in lymph node biopsies of B-cell lymphoma and Hodgkin’s disease, and its association with EBV infection. Int J Immunopathol Pharmacol. 2003; 16(2):109–18. https://doi.org/10.1177/039463200301600204 PMID: 12797901

11. de Villiers EM, Schmidt R, Delius H, zur Hausen H. Heterogeneity of TT virus related sequences isolated from human tumour biopsy specimens. J Mol Med (Berl). 2002; 80(1):44–50. https://doi.org/10.1007/s001090100281 PMID: 11862324

12. Focosi D, Macera L, Boggi U, Nelli LC, Maggi F. Short-term kinetics of torque teno virus viremia after induction immunosuppression confirm T lymphocytes as the main replication-competent cells. J Gen Virol. 2015; 96(Pt 1):115–7. https://doi.org/10.1099/vir.0.070094-0 PMID: 25304651

13. Focosi D, Macera L, Pistello M, Maggi F. Torque Teno virus viremia correlates with intensity of maintenance immunosuppression in adult orthotopic liver transplant. J Infect Dis. 2014; 210(4):667–8. https://doi.org/10.1093/infdis/jiu209 PMID: 24688076

14. Focosi D, Maggi F, Albani M, Macera L, Ricci V, Gragnani S, et al. Torquetenovirus viremia kinetics after autologous stem cell transplantation are predictable and may serve as a surrogate marker of functional immune reconstitution. J Clin Virol. 2010; 47(2):189–92. https://doi.org/10.1016/j.jcv.2009.11.027 PMID: 20034850
15. Frye BC, Bierbaum S, Falcone V, Kohler TC, Gasplma yr M, Hettich I, et al. Kinetics of Torque Teno Virus-DNA Plasma Load Predict Rejection in Lung Transplant Recipients. Transplantation. 2019; 103 (4):815–22. https://doi.org/10.1097/TP.0000000000002436 PMID: 30234787

16. Gorzer I, Haloschan M, Jaksch P, Klepetko W, Puchhammer-Stockl E. Plasma DNA levels of Torque teno virus and immunosuppression after lung transplantation. J Heart Lung Transplant. 2014; 33 (3):320–3. https://doi.org/10.1016/j.healun.2013.12.007 PMID: 24559947

17. Gilles R, Herling M, Holtick U, Heger E, Awerkiew S, Fish I, et al. Dynamics of Torque Teno virus viremia could predict risk of complications after allogeneic hematopoietic stem cell transplantation. Med Microbiol Immunol. 2017; 206(5):355–62. https://doi.org/10.1007/s00430-017-0511-4 PMID: 28702856

18. Gorzer I, Jaksch P, Kundi M, Seitz T, Klepetko W, Puchhammer-Stockl E. Pre-transplant plasma Torque Teno virus load and increase dynamics after lung transplantation. PLoS One. 2015; 10(3): e0122975. https://doi.org/10.1371/journal.pone.0122975 PMID: 25894323

19. Norden R, Magnusson J, Lundin A, Tang KW, Nilsson S, Lindh M, et al. Quantification of Torque Teno Virus and Epstein-Barr Virus Is of Limited Value for Predicting the Net State of Immunosuppression After Lung Transplantation. Open Forum Infect Dis. 2018; 5(4):ofy050. https://doi.org/10.1093/ofid/ofy050 PMID: 29644247

20. Jaksch P, Kundi M, Gorzer I, Murakozy G, Lambers C, Benazzo A, et al. Torque Teno Virus as a Novel Biomarker Targeting the Efficacy of Immunosuppression After Lung Transplantation. J Infect Dis. 2018; 218(12):1922–8. https://doi.org/10.1093/infdis/jiy452 PMID: 30053048

21. Strassl R, Doberer K, Rasoul-Rockenschaub S, Herker H, Görzer I, Kläger JP, et al. Torque Teno Virus for Risk Stratification of Acute Biopsy-Proven Alloreactivity in Kidney Transplant Recipients. J Infect Dis. 2018; 219(12):1934–9. https://doi.org/10.1093/infdis/jiz039 PMID: 30668796

22. Ruiz P, Martinez-Picola M, Santana M, Munoz J, Perez-Del-Pulgar S, Koutsoudakis G, et al. Torque Teno Virus Is Associated With the State of Immune Suppression Early After Liver Transplantation. Liver Transpl. 2019; 25(2):302–10. https://doi.org/10.1002/lt.25374 PMID: 30375165

23. Zhong S, Yeo W, Tang MW, Lin XR, Mo F, Ho WM, et al. Gross elevation of TT virus genome load in the peripheral blood mononuclear cells of cancer patients. Ann N Y Acad Sci. 2001; 945:84–92. https://doi.org/10.1111/j.1749-6632.2001.tb03868.x PMID: 11708500

24. Sawata T, Bando M, Nakayama M, Mato N, Yamasawa H, Takahashi M, et al. Clinical significance of changes in Torque teno virus DNA titer after chemotherapy in patients with primary lung cancer. Respir Investig. 2018; 56(2):173–8. https://doi.org/10.1016/j.resinv.2017.12.004 PMID: 29548656

25. Maggi F, Pistello M, Vatteroni M, Presciutti M, Marchi S, Isola P, et al. Dynamics of persistent TT virus infection, as determined in patients treated with alpha interferon for concomitant hepatitis C virus infection. J Virol. 2001; 75(24):11999–2004. https://doi.org/10.1128/JVI.75.24.11999-12004.2001 PMID: 11711590

26. Maggi F, Pifferi M, Fornai C, Andreoli E, Tempestini E, Vatteroni M, et al. TT virus in the nasal secretions of children with acute respiratory diseases: relations to viremia and disease severity. J Virol. 2003; 77(4):2418–25. https://doi.org/10.1128/jvi.77.4.2418-2425.2003 PMID: 12581979

27. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001; 28(5):481–504. https://doi.org/10.1023/a:1012299115260 PMID: 11768292

28. Huang LY, Oystein Jonassen T, Hungnes O, Grinde B. High prevalence of TT virus-related DNA (90%) and diverse viral genotypes in Norwegian blood donors. J Med Virol. 2001; 64(3):381–6. https://doi.org/10.1002/jmv.1062 PMID: 11424130

29. Giacconi R, Maggi F, Macera L, Spezia PG, Pistello M, Provinciali M, et al. Prevalence and Loads of Torquetenovirus in the European MARK-AGE Study Population. The Journals of Gerontology: Series A. 2019.

30. Westman G, Schoofs C, Ingelsson M, Järhult JD, Muradrasiol S. Torque teno virus viral load is related to age, CMV infection and HLA type but not to Alzheimer’s disease. PLoS One. 2020; 15(1):e0227670.

31. Haloschan M, Bettesch R, Gorzer I, Weseslindtner L, Kundi M, Puchhammer-Stockl E. TT V DNA plasma load and its association with age, gender, and HCMV IgG serostatus in healthy adults. Age (Dordr). 2014; 36(5):9716.